1. INTRODUCTION {#sec1}
===============

Guangxi Zhuang Autonomous Region (Guangxi) has a population of 47 million and is one of five provincial-level autonomous regions in China (other autonomous regions include Xinjiang, Tibet, Ningxia, and Inner Mongolia). Guangxi is located in southwest China, borders Vietnam, and is in close proximity to the "Golden Triangle", a region known for the production of illegal narcotics which sits at the intersection of Myanmar, Laos, and Thailand \[[@r1]-[@r6]\]. In 1996, the first HIV case in Guangxi was identified among people who inject drugs (PWID). Between 1996 and 2003, PWID represented 69% of all reported HIV cases \[[@r7]\]. However, in 2006, the primary transmission route in Guangxi shifted to heterosexual intercourse (Fig. **[1](#f1){ref-type="fig"}**) \[[@r8]\]. By the end of 2004, Guangxi had the third highest number of HIV cases reported among provincial-level regions in China \[[@r9]\]. In 2013, Guangxi accounted for 12% of total HIV incidence in China, while only representing less than 4% of the national population \[[@r10]\].

2. HIV TRANSMISSION AND DRUG USE {#sec2}
================================

Following liberation in 1949, China launched a mass anti-drug campaign that mobilized the entire nation. Consequently, serious narcotic addiction problems were largely eliminated until 1953 \[[@r4]\]. The use of illicit substances reemerged in China in the 1980s after China adopted an open-door policy which was associated with global drug trafficking activities \[[@r5]\]. These economic changes had a profound impact in Southwest China due to its close proximity to the "Golden Triangle". The majority of heroin in China is trafficked from Myanmar (Burma), Laos, and Thailand into Yunnan and Guangxi, or from Vietnam into Guangxi, and then into other neighbor provinces (*e.g.*, Sichuan, Guizhou, and Xinjiang and another to Guangdong, Shanghai, and Beijing) \[[@r1]-[@r6], [@r11]-[@r15]\]. From 1990 to 2009, the number of people using drugs registered by Chinese public security departments increased from 70,000 in 1990 to 1.22 million in 2009, an annual increase of 10% \[[@r6], [@r16]\]. However, the estimated number of actual people using drugs is 3-8 times the reported number \[[@r6], [@r16]\].

The first HIV case among People Who Inject Drugs (PWID) in China was reported in the southwestern province of Yunnan along the border with Burma (Myanmar) in 1989 \[[@r17]\]. Thereafter, the HIV epidemic among PWID rapidly spread north to other parts of the country. By 2002, HIV infection among PWID had been detected in all 31 mainland provinces, and HIV infection through injection drug use accounted for 64% of all reported HIV/AIDS cases in China \[[@r18], [@r19]\]. In 1996 when the first case of HIV was detected in Guangxi, most reported HIV cases were attributed to injection drug use. From 1996 to 2005, the number of counties in Guangxi that reported HIV cases increased from seven to all 115 \[[@r20]\]. In 1998, about 60% of HIV infected individuals reported sharing needles and the HIV infection prevalence among PWID at baseline was 15.4% \[[@r21]\]. In one study from 1998-1999, the HIV incidence among PWID increased from 2.38 to 6.86 per 100 person-years (py) \[[@r22]\]. Another prospective cohort study found that HIV prevalence among PWID at baseline was 25% and the HIV incidence rate was 3.1 per 100 person-years at 12 months of follow-up \[[@r23], [@r24]\]. HIV prevalence among PWID increased rapidly after 1996, with an annualized increase of 10% until 2011 \[[@r25]\]. (Fig. **[1](#f1){ref-type="fig"}**-**[3](#f3){ref-type="fig"}**).

3. HIV TRANSMISSION AND SEXUAL INTERCOURSE {#sec3}
==========================================

In response to an epidemic of Sexually Transmitted Infections (STI), China launched a nationwide STI control campaign throughout the 1950s that entailed shutting down brothels, screening and treatment of STI, and mass media education and prevention \[[@r26], [@r27]\]. By the end of 1964, syphilis infections were essentially eliminated \[[@r28], [@r29]\]. However, after adopting an open door policy and free market principles in 1978, China experienced rapid economic development, large income disparities, changing notions of sexuality, and increased commercial sex activities. The Chinese Public Security Office estimated that there were 4 to 6 million sex workers nationwide in 2000, an increase of 160-fold compared to in 1985 \[[@r28], [@r29]\]. During this same period, cases of eight reportable STIs (including syphilis and HIV) in China increased 147-fold, from 5838 to 859040 \[[@r30]\].

The HIV epidemic in Guangxi was initially fueled by injection drug use, but since 2006 the main mode of HIV transmission has been heterosexual sex \[[@r8]\]. From 2000 to 2013, the proportion of new HIV cases attributed to heterosexual sex rose from less than 10% to over 90%. This rising risk of HIV sexual transmission among the heterosexual population is alarming because it raises the potential for a more diffuse and generalized epidemic \[[@r31]\]. Among Female Sex Workers (FSW), HIV prevalence was above 1.0% from 1998 to 2011 but has remained below 1.0% since 2013 \[[@r32]\]. The age groups most afflicted by the epidemic have also shifted. In 2000, the older population (≥50 years of age) as a proportion of reported HIV cases increased from less than 4% to over 40% in 2013 (Fig. **[1](#f1){ref-type="fig"}**-**[3](#f3){ref-type="fig"}**).

Given the paucity of data on HIV risk among older individuals in China, a large-scale cross-sectional survey was conducted in 2012 to understand HIV and STI risk factors among older male clients of FSW in Guangxi, China \[[@r33]-[@r38]\]. This study found that the overall prevalence of HIV and syphilis infection was 3.0% and 3.2%, respectively. Factors associated with HIV or syphilis infection included recent non-commercial casual sex, \>10 years of commercial sex history, \>2 incidents of commercial sex in last month and aphrodisiac use \[[@r32]-[@r34]\]. One important finding was that 29.8% of participants used aphrodisiacs \[[@r32]-[@r34]\]. In 2013, a population-based prospective HIV follow-up study in three rural counties in Guangxi was conducted \[[@r35]\]. HIV prevalence was 0.29% among all study participants aged ≥20 years at baseline. Overall HIV incidence was 2.73 per 10000 person-years (235/860,627 PY). HIV seroconversion was associated with males, older age, and not currently being married. HIV incidence was 71.28 per 10000-years among males aged 50-69 years who had less than secondary schooling and were divorced or widowed. Heterosexual sex was the dominant transmission mode for HIV seroconversions (99.0%). Among males who seroconverted, 79% had sex with female sex workers and 18% had sex with casual sexual partners, but not sex workers. Among females who seroconverted, 62% and 37% were infected through their spouse or steady sexual partners, and casual sexual partners, respectively. This study was among the first to provide empirical evidence that current HIV prevention strategies designed primarily for key populations may be insufficient for addressing HIV transmission among the older, general population.

In China, approximately 2% to 5% of sexually active Chinese men have sex with other men. This corresponds to about 2 to 8 million men who have sex with men (MSM) in China \[[@r39]\]. HIV transmission among MSM is increasing at an alarming speed \[[@r40]-[@r57]\]. The proportion of reported HIV cases in China attributed to MSM increased from 3.5% in 2007 to 28.3% in 2015 \[[@r58], [@r59]\]. However, the proportion of reported HIV cases due to MSM remains relatively low in Guangxi. In 2013, only 2.3% of HIV cases in Guangxi were among MSM \[[@r10]\]. Nonetheless, annual cross-sectional surveys among MSM in Guangxi indicate that HIV prevalence increased from 2.0% in 2008 to 10.0% in 2017 \[[@r60]\] (Fig. **[3](#f3){ref-type="fig"}**). HIV preventative measures among MSM remain urgently needed. Mental health interventions may help reduce MSM sexual risk behaviors \[[@r61]-[@r63]\]. HIV risk factors among MSM in Guangxi include recent unprotected anal intercourse with commercial male partners, recent sex with female partners, past drug use, and syphilis infection \[[@r60]\] Figs. (**[1](#f1){ref-type="fig"}**-**[3](#f3){ref-type="fig"}**).

4. HIV MOLECULAR EPIDEMIOLOGY {#sec4}
=============================

Two different HIV subtypes have been introduced to southwest China. In the early phases of the epidemic in Yunnan among PWID, the dominant HIV subtypes were subtype B strains, including both North American-like subtype B strains and the Thailand variant of subtype B (B′ or Thai B) \[[@r64], [@r65]\]. HIV subtype C strain was similar to Indian subtype C and was first found among PWID in 1992 in Yunnan \[[@r66]\]. Thereafter, a circulating recombinant form (CRF) CRF01\_ AE was identified in a female who came back to Yunnan after commercial sex work in Thailand in 1994 \[[@r66]\].

Molecular epidemiological studies indicate that HIV subtype C and subtype E among PWID probably spread from Yunnan to Baise county, Guangxi and from Vietnam into Pingxiang county in Guangxi through drug trafficking and injection drug use \[[@r67]\]. In 1998, the low inter-person nucleotide diversity among PWID in northern Vietnam showed that HIV subtype E was introduced recently among PWID in northern Vietnam, suggesting transborder transmission as the likely source of HIV subtype E being imported into Guangxi \[[@r68], [@r69]\]. During this period, B/C recombinants were identified among PWID from Baise county, Guangxi, a mountainous region near the Yunnan-Guangxi border, and CRF01\_ AE strains were found among PWID in Nanning, the capital of Guangxi, and in Pingxiang county near the China- Vietnam border \[[@r70]\]. In 2000, PWID in Pingxiang and Bin-yang counties of Guangxi were found to be infected with CRF08_BC \[[@r71]\].

Following the rise of sexually transmitted HIV in Guangxi, China, multiple HIV subtypes were identified among HIV patients infected by heterosexual infection: CRF01_AE (80.1%), CRF07_BC (6.4%), CRF08_BC (10.2%), subtype B (1.7%), and URFs (1.7%) \[[@r72]\]. This study identified two large CRF01_AE clusters: one cluster originating from Vietnam among PWID and one novel cluster similar to strains from Fujian province, China. In 2008-2009, a survey in Guangxi indicated that CRF01_AE was the dominant subtype (77.6%), followed by CRF08_BC (10.7%) and CRF07_BC (7.4%), 7 unique recombinant forms, 4 subtype B (B\'), and 1 subtype G \[[@r73]\]. Using a Bayesian discrete phylogeographic approach to analyze the transmission source of strains among recently infected HIV patients throughout Guangxi in 2012-2013, one study indicated the following subtype/CRF distribution: CRF01_AE (61.1%), CRF07_BC (18.8%), CRF08_BC (16.6%), CRF55_01B (3.1%), and subtype B\' (0.4%). Recent research determined that most sequenced transmission strains were derived from already-circulating local strains (93.0%) and that only individuals 18-25 years old were significantly associated with transmission from outside Guangxi \[[@r74]\].

5. HIV TREATMENT AND PREVENTION {#sec5}
===============================

The Chinese government quickly assumed leadership and commitment of resources in responding to the growing HIV epidemic in China. The national AIDS prevention and care budget increased from 0.3 billion RMB in 2000 to 2 billion RMB in 2006. The most impactful program in the National AIDS Control Policy was the "Four Frees and One Care" program, which was implemented in 2003 and aimed to provide free voluntary counseling and testing, free antiretroviral treatment, free Prevention of Mother to Child Transmission (PMTCT), free education to AIDS orphans, and financial assistance and social support to people living with HIV \[[@r75]\]. Supported by this policy, harm reduction programs such as Methadone Maintenance Therapy (MMT), needle exchange, and condom promotion were implemented in 2004 \[[@r76]-[@r81]\].

The Chinese National Free Antiretroviral Treatment Program (NFATP) was initiated in 2002 and has significantly reduced death in HIV patients \[[@r82]-[@r86]\]. From 2003-2008, free antiretroviral therapy (ART) was provided to HIV patients with CD4+ T cell counts less than 200 cells/uL. From 2008-2012, guidelines were updated so that HIV patients with CD4+ T cell counts less than 350 cells/uL could access free ART. After 2012, all HIV patients could access free ART, irrespective of their CD4 T cell count \[[@r84]-[@r86]\]. First-line HAART regimens before 2008 consisted of \[azidothymidine (AZT) or stavudine (D4T)\] + \[didanosine (DDI) or lamivudine (3TC)\] + \[nevirapine (NVP) or efavirenz (EFV)\], and then revised to consist of \[tenofovir (TDF) or azidothymidine (AZT)\] + lamivudine (3TC) + \[efavirenz (EFV) or nevirapine (NVP)\] \[[@r84]-[@r90]\]. This program included three phases: initiation to 2005, 2005-2007 (first scale-up), and 2008-present (further scale-up and standardization). During these three phases, Guangxi, respectively, initiated more than 190, 4100, and 57500 HIV patients (at least 18 years old) on ART by the end of 2016. The average mortality rate was 2.6 deaths per 100 person-years among HIV patients who initiated ART during 2008-2013 in Guangxi \[[@r87]\]. The mortality rates per 100 person-years by year post-ART initiation was 5.4 in the first year, 1.8 in the second year, 1.3 in the third year, 1.2 in the fourth year, and less than 1.0 after four years on ART. Mortality rates in this study were significantly lower than other studies in China but higher than in studies from Europe and North America \[[@r88], [@r91]-[@r93]\], especially the high mortality rate during the first year post-ART initiation. The average mortality and ART attrition rates among all patients who initiated ART between 2010 and 2015 in Guangxi were 2.63 deaths and 5.32 attritions per 100 person-years, respectively \[[@r94]\]. High CD4 counts (pre-ART CD4 counts [\>]{.ul}500 cells/ul) was strongly associated with attrition (stop ART or lost to follow-up). One major concern with initiating ART among patients with a high CD4+ cell count is increased risk of poor adherence \[[@r94], [@r95]\]. Improving quality of care remains a considerable challenge in ART treatment.

In order to achieve significant future reductions in HIV transmission and HIV-related mortality, China's government implemented the World Health Organization's 90--90--90 policy (90% of the people living with HIV know their HIV status, 90% of the people who know their HIV-positive status are accessing treatment, and 90% of the people receiving treatment have suppressed viral loads). By the end of 2017, 70.2% of the people living with HIV knew their HIV status, 76.8% of the people who knew their HIV-positive status were receiving treatment, and 96.8% of the people receiving treatment had suppressed viral loads in Guangxi \[[@r96]\]. An observational cohort study of HIV epidemiology and treatment databases among serodiscordant couples in Guangxi showed that HIV seroincidence rate was significantly higher among the treatment-naive group (4.2 per 100 person-years, 3.7-4.8) compared with the treatment group (1.6 per 100 person-years, 1.3-1.8) \[[@r97]\]. This corresponded to an overall 45% reduction in risk of HIV transmission among serodiscordant couples who were on ART treatment. Drug adherence and baseline viral load among partners in the treatment were significantly associated with an increased risk of HIV seroincidence \[[@r98]\]. Treatment-as-prevention was feasible on a regional scale, but comprehensive harm reduction programs are urgently needed for serodiscordant couples.

In 2006-2007, surveys in Guangxi found that after initiation of first-line ART, 99.1% of HIV patients had viral loads \<1000 copies/ml and 0.0% of HIV patients had ART drug resistance after 12 months of treatment \[[@r99], [@r100]\]. A series of cross-sectional surveys among HIV patients receiving first-line ART from 2004 to 2012 in Guangxi indicated that the prevalence of virologic suppression and drug resistance was 95.4% and 2.8%, respectively \[[@r101]\]. Among HIV patients who had a viral load ≥1000 copies/ml, 54.5% were resistant to Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTIs) drugs, 90.9% were resistant to nucleoside reverse transcriptase inhibitor (NRTIs) drugs, and 4.5% of patients had drug resistance to Protease Inhibitors (PIs). Moreover, the trend chi-square test showed that the proportion of HIV patients achieving virologic suppression increased over time from 2004 to 2012. From 2005-2010, the overall prevalence of transmitted HIV Drug Resistance (TDR) in Guangxi was 3.2% among antiretroviral-naive HIV patients \[[@r102]\]. A survey among patients from newly diagnosed HIV infected 16-25 years olds in Guangxi from 2009 to 2013 showed that TDR mutations were 4.6%, with 1.4%, 1.4%, and 2.3% with resistance to PIs, NRTIs, and NNRTIs, respectively \[[@r103]\]. These excellent treatment outcomes in Guangxi can be explained by several factors. First, provincial, prefecture, and county hospitals are all providing ART for HIV patients. One provincial hospital provides technical support and training to each prefecture hospital, which then provides technical assistance to each county hospital. Second, all HIV patients receive treatment in hospitals, while community care and outreach are provided through local health workers.

In response to the HIV epidemic, the Guangxi government launched a Guangxi AIDS Conquering Project (GACP) in 2010 \[[@r104]\]. In 2013, the Guangxi People's Congress passed the "Regulations on AIDS Prevention and Control in Guangxi" to foster a supportive social environment for AIDS control. The Guangxi government integrated local initiatives with the national Four Frees and One Care AIDS control policy, thus efficiently leveraging financial and human resource investments to enhance HIV prevention education, HIV testing and counselling, surveillance, health interventions, medical care, and antiretroviral therapies. By the end of 2014, AIDS control health/management staff increased by 357 and 2015 at prefectural and county level public health institutions, respectively. The Guangxi budget for AIDS prevention and treatment was 2.1 billion Yuan RMB during 2010-2014, including national and local investments.

Since GACP was initiated in 2011, HIV prevention efforts in Guangxi were greatly enhanced to expand access to HIV testing, ART, and other intervention measures. Guangxi's HIV testing (per 100 persons) rapidly increased from 7.1 in 2009 to 15.0 in 2016 and was more than 2.0 times that of the national average. The Guangxi ART coverage rate increased from 23% in 2009 to 50% in 2016. In addition, the number of reported HIV/AIDS cases in Guangxi decreased from 2013 to 2017. From 2009-2015, the prevalence of HIV, HCV, and syphilis among PWID decreased from 13.0% to 6.2%, 68.0% to 50.5%, and 8.5% to 5.2%, respectively \[[@r105]\]. Such declines coincide with an increase in the use of prevention services, methadone maintenance therapy or needle exchange, peer education, and HIV testing and knowledge of HIV status increased over time during 2009-2015. HIV prevalence also declined significantly among high-tier, middle-tier, and low-tier FSWs over time from 2010 to 2015 \[[@r106]\]. However, HIV prevalence increased for older age (≥50 years old) clients of FSW, particularly among older clients who prefer low-tier FSWs.

CONCLUSION
==========

From 1996 to 2017, the dominant mode of HIV transmission in Guangxi shifted from injection drug use to heterosexual sex. This rising risk of HIV sexual transmission among the heterosexual population is alarming because it raises the potential for a more diffuse and generalized epidemic, especially among older heterosexual adults in rural areas. The local GACP initiative combined with the National AIDS Control Policy appears to have helped stabilize HIV incidence in Guangxi, but additional interventions are needed to address HIV risk among older male clients of FSW.

Declared none.

CONSENT FOR PUBLICATION
=======================

Not applicable.

FUNDING
=======

This study was supported by grants from the Ministry of Science and Technology of China (2018ZX10721102-006, 2018ZX10715008), the Guangxi Medical and Health Project (Z20170126), Guangxi Science and Technology Bureau (AB16380213), Guangxi Honor Scholar, Chinese State Key Laboratory for Infectious Disease Develop Grant.

CONFLICT OF INTEREST
====================

The authors declare no conflict of interest, financial or otherwise.

![Reported HIV/AIDS cases by year and route of HIV infection in Guangxi, China.](CHR-17-85-f1){#f1}

![Reported HIV/AIDS cases by age (years) in Guangxi, China.](CHR-17-85-f2){#f2}

![HIV prevalence over time in serial cross-sectional surveys among people who inject drugs, FSWs and MSM in Guangxi, China.](CHR-17-85-f3){#f3}
